Loading…
Erasca, Inc. is projected to rise to $22.28 by 2027, a +20% move from its current price of $18.53. ERAS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.81 | $18.54 | $19.30 | +0.07% |
| Jul 14 | $17.53 | $18.55 | $19.64 | +0.13% |
| Jul 15 | $17.32 | $18.57 | $19.91 | +0.20% |
| Jul 16 | $17.14 | $18.58 | $20.14 | +0.27% |
| Jul 17 | $16.99 | $18.59 | $20.34 | +0.34% |
| Jul 18 | $16.86 | $18.61 | $20.53 | +0.40% |
| Jul 19 | $16.74 | $18.62 | $20.71 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.74 | $18.62 | $20.71 | +0.47% |
| Week 2 | $16.09 | $18.71 | $21.74 | +0.95% |
| Week 3 | $15.63 | $18.79 | $22.60 | +1.42% |
| Week 4 | $15.26 | $18.88 | $23.36 | +1.90% |
| Week 5 | $14.95 | $18.97 | $24.07 | +2.39% |
| Week 6 | $14.69 | $19.06 | $24.74 | +2.87% |
| Week 7 | $14.45 | $19.15 | $25.38 | +3.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
The company has license agreements with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.
The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
ERAS is a healthcare stock trading at $18.29 per share, with a market cap of $5.69B and a rank of 1231. The forecast landscape suggests a rising price path over the coming years, with the 2026 average at $18.29 and longer-horizon milestones including $42.07 by 2030, $101.06 by 2040, and $285.92 by 2050. The forecast shows progressively higher averages and rising ROIs, reaching 130 by 2030, 452.6 by 2040, and 1463.2 by 2050, all labeled with bullish sentiment for the later years.
These are estimates and not guarantees, and actual results may differ.
A major floor 50.8% below — a decisive break under it would weaken the trend.
The nearest floor, 35.4% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 28.3% above — clearing it would confirm fresh momentum.
Key ERAS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERAS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.76 | Sell | $18.61 | Sell |
| MA 10 | $18.28 | Buy | $17.99 | Buy |
| MA 20 | $16.32 | Buy | $16.73 | Buy |
| MA 50 | $13.37 | Buy | $15.07 | Buy |
| MA 100 | $14.61 | Buy | $13.57 | Buy |
| MA 200 | $9.65 | Buy | $10.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.45 | Neutral |
| Stoch RSI (14) | 45.45 | Neutral |
| CCI (20) | 74.00 | Neutral |
| Williams %R (14) | -15.37 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | 22.96 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 84.63 | Sell |
| TRIX (15) | 1.38 | Buy |
| Awesome (5,34) | 3.94 | Buy |
| Ultimate (7,14,28) | 62.88 | Neutral |
| Momentum (10) | 3.58 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 19.02 | Sell |
| ADX (14) | 29.67 | Buy |
| ATR (14) | 0.56 | Info |
The 30-day technical picture is bullish. RSI14 is 70, with a SMA50 of $13.56 and a SMA200 of $8.97. The thirty-day price range runs from $13.27 to $25.22, illustrating sideways-to-upward movement within a defined band. Current price is $18.29, with a support level at $10.23 and a resistance at $18.29.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $18.53 | $27.70 | 0% | Neutral | |
| $16.96 | $22.28 | $31.39 | +20% | Bullish | |
| $18.24 | $25.02 | $37.10 | +35% | Bullish | |
| $24.22 | $34.46 | $53.14 | +86% | Bullish | |
| $29.54 | $43.42 | $69.20 | +134% | Bullish | |
| $34.34 | $52.02 | $85.29 | +181% | Bullish | |
| $35.13 | $54.74 | $92.06 | +195% | Bullish | |
| $33.70 | $53.95 | $92.82 | +191% | Bullish | |
| $38.08 | $62.54 | $109.87 | +238% | Bullish | |
| $45.78 | $77.09 | $138.07 | +316% | Bullish | |
| $58.09 | $109.86 | $213.13 | +493% | Bullish | |
| $136.43 | $303.18 | $659.18 | +15.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.49 | $18.53 | $22.22 | +0.00% |
| August 2026 | $16.02 | $19.16 | $23.70 | +3.40% |
| September 2026 | $16.31 | $19.70 | $24.77 | +2.84% |
| October 2026 | $15.92 | $19.41 | $24.72 | -1.50% |
| November 2026 | $16.22 | $19.93 | $25.68 | +2.71% |
| December 2026 | $17.20 | $21.28 | $27.70 | +6.77% |
Click any year to see its month-by-month ERAS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ERAS could reach as high as $27.70, with a base case around $18.53 and support toward $3.49 — roughly 0% from $18.53. Price action looks broadly range-bound.
Expect ERAS to range from $16.96 to $31.39 through 2027. The $22.28 average target implies a +20% move from current prices. That is up +20% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ERAS price prediction for 2028 points to an average of $25.02 (low $18.24, high $37.10) — a potential gain of +35% on today's $18.53. Momentum favours further upside here.
In 2029, ERAS is projected to trade between $24.22 and $53.14, averaging $34.46 — a potential gain of +86% from today's $18.53. That is up +38% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Erasca, Inc.'s 2030 outlook centres on $43.42, within a $29.54 to $69.20 range. That is up +26% on the projected 2029 average. That marks a +134% change versus current levels. Momentum favours further upside here.
By 2031, ERAS could reach as high as $85.29, with a base case around $52.02 and support toward $34.34 — roughly +181% from $18.53. Buyers look set to stay in control over this stretch.
Expect ERAS to range from $35.13 to $92.06 through 2032. The $54.74 average target implies a +195% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The ERAS price prediction for 2033 points to an average of $53.95 (low $33.70, high $92.82) — a potential gain of +191% on today's $18.53. Buyers look set to stay in control over this stretch.
In 2034, ERAS is projected to trade between $38.08 and $109.87, averaging $62.54 — a potential gain of +238% from today's $18.53. That is up +16% on the projected 2033 average. Momentum favours further upside here.
Erasca, Inc.'s 2035 outlook centres on $77.09, within a $45.78 to $138.07 range. That is up +23% on the projected 2034 average. That marks a +316% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ERAS could reach as high as $213.13, with a base case around $109.86 and support toward $58.09 — roughly +493% from $18.53. Momentum favours further upside here.
Expect ERAS to range from $136.43 to $659.18 through 2050. The $303.18 average target implies a +15.4x move from current prices. That is up +176% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ERAS today (≈ 53.966541 ERAS) could be worth
$16,361.43
+$15,361.43 (+1536%) by 2050 · US Dollar
Based on the average projected ERAS price of $303.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERASwould be worth at today's price.
$1,000 invested in ERAS on Jul 10, 2025 (≈ 657.894745 ERAS) would be worth
$12,190.79
+$11,190.79 (+1119.1%) today · 12.19× · US Dollar
Based on a ERAS entry price of $1.52 vs. today's $18.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.47 | $1,003.25 | +0.3% |
| 1 month ago | $13.37 | $1,385.94 | +38.6% |
| 3 months ago | $17.01 | $1,089.36 | +8.9% |
| 6 months ago | $6.23 | $2,974.32 | +197.4% |
| 1 year ago | $1.52 | $12,190.79 | +1119.1% |
| All time (5.0y) ago | $17.43 | $1,063.11 | +6.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERAS forecast.
Our base-case forecast reaches $37.00 around 2030.
Implied market cap at $37.00: $11.51B
The multi-year forecast shows a bullish trajectory from 2027 onward, with higher average prices and expanding upside potential into the 2030s and 2040s. In 2030 the average price is forecast at $42.07, with a min of $26.90 and a max of $70.97, and a ROI of 130, signaling meaningful upside despite inherent uncertainties. The 2040 forecast reaches an average of $101.06 (min $46.11, max $212.80) with a ROI of 452.6, while 2050 projects an average of $285.92 (min $128.66, max $657.61) and a ROI of 1463.2.
Overall sentiment remains BULLISH across 2030, 2040, and 2050. These are estimates, not guarantees, and depend on a range of market and company-specific factors.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $42.07, a low of $26.90, and a max of $70.97, with a ROI 130 and bullish sentiment.
The forecast points to a rising price path with bullish sentiment from 2027 onward, with an average price of $42.07 by 2030 and $285.92 by 2050, and ROIs of 130 by 2030, 452.6 by 2040, and 1463.2 by 2050. These are estimates and not guarantees.
Yes. The forecast max prices include $112.08 in 2034, $141.46 in 2035, $212.80 in 2040, and $657.61 in 2050.
The 30-day picture is bullish. RSI14 is 70, SMA50 is $13.56, SMA200 is $8.97, and the thirty-day range is $13.27 to $25.22. The current price is $18.29, with support at $10.23 and resistance at $18.29.
ERAS trades at $18.29 per share with a market cap of $5.69B and a rank of 1231.
Erasca, Inc. Community Discussion
0Share your Erasca, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.